News
-
-
-
-
-
-
PRESS RELEASE
Heidelberg Pharma AG and Huadong Medicine Receive NMPA Approval for Clinical Trial of HDP-101 Combination Therapy in China
Heidelberg Pharma AG and Huadong Medicine receive NMPA approval for Phase Ib/II clinical trial of HDP-101 combination therapy in China. Evaluation of BCMA-targeting ADC in patients with multiple myeloma -
-
-
-
REGULATED PRESS RELEASE
Altarea: Comprehensive settlement agreement reached, ending the dispute between Altarea and the shareholders of the Praemia group (formerly Primonial group)
Altarea and Praemia group settle dispute with comprehensive agreement, including settlement payment of €10 million. Praemia strengthens equity base with €60 million subscription by Altarea